Atrial Fibrillation Recurrence Following Cardioversion: the Role of Clinical Factors and Alpha Defensin Levels
Not Applicable
- Conditions
- Atrial Fibrillation
- Interventions
- Procedure: Cardioversion
- Registration Number
- NCT04155879
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
Atrial fibrillation and inflammation are strongly correlated. The aim of this study is to evaluate whether inflammation markers (alpha Defensin) predict maintenance of sinus rhythm following cardioversion. A secondary aim is to evaluate the role of Colchicine, an anti-inflammatory medication, in reducing the recurrence rate of atrial fibrillation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Atrial fibrillation
- Candidate for cardioversion
Exclusion Criteria
- Colchicine allergy
- Hepatic or renal failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment group Colchicine Tablets This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months Treatment group Cardioversion This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
- Primary Outcome Measures
Name Time Method Recurrence of atrial fibrillation 12 months Atrial fibrillation recurrence rates over the next 12 months will be determined based on medical records and ECG documentation between treatment group (Colchicine) and control group.
- Secondary Outcome Measures
Name Time Method Alpha Defensin levels in patients with recurrence of atrial fibrillation 12 months Alpha Defensin levels will be measured in patients with recurrence of atrial fibrillation and compared to levels in patients without recurrence.
Trial Locations
- Locations (1)
Hillel Yaffe Medical Center
🇮🇱Hadera, Israel